FDA Approves SOLIQUA 100/33 — Sanofi-Aventis U.S. LLC

# FDA Approves Sanofi's SOLIQUA 100/33, a Fixed-Dose Combination Insulin and GLP-1 Receptor Agonist Sanofi-Aventis U.S. LLC received FDA approval for SOLIQUA 100/33 (insulin glargine and lixisenatide), positioning the company to capture market share in the competitive diabetes treatment segment by offering a convenient once-daily injection that combines two complementary mechanisms of action. The fixed-dose combination is expected to appeal to type 2 diabetes patients seeking simplified dosing reg